CLINICAL SIGNIFICANCE OF ULTRASOUND EXAMINATION IN HEPATIC STEATOSIS
Keywords:
Metabolic dysfunction-associated steatotic liver disease, hepatic steatosis, fatty liver, ultrasound diagnostics, ultrasonography, CAP, UGAP, elastography, shear-wave elastography, fibrosis, metabolic syndrome.Abstract
Hepatic steatosis (non-alcoholic fatty liver disease) is one of the most common metabolic disorders in modern medicine, characterized by the pathological accumulation of triglycerides in the tissues. Since the disease often remains asymptomatic for a prolonged period, early detection and the prevention of complications (such as steatohepatitis and cirrhosis) constitute a pressing issue. Ultrasound examination (US) plays a leading role in the initial diagnosis of hepatic steatosis due to its non-invasive nature, cost-effectiveness, and safety.
Relevance. Steatotic liver disease associated with metabolic dysfunction is one of the most common forms of liver disease and is closely linked to cardiometabolic risk factors such as obesity, type 2 diabetes mellitus, insulin resistance, arterial hypertension, and dyslipidemia. Given that the early stages of the disease are often clinically asymptomatic, non-invasive instrumental diagnostic methods are of great importance for early detection.
The aim of the study is to analyze the modern capabilities of ultrasound examination in detecting hepatic steatosis, its key diagnostic signs, advantages and limitations, as well as the clinical significance of new quantitative ultrasound technologies. Materials and Methods. Clinical guidelines, systematic reviews, and contemporary scientific studies published between 2024 and 2026 were analyzed. The primary focus was on B-mode ultrasonography, Controlled Attenuation Parameter (CAP), Ultrasound-Guided Attenuation Parameter (UGAP), shear-wave elastography, and artificial intelligence-based ultrasound diagnostics.
Results. In conventional B-mode ultrasound, key signs of hepatic steatosis include increased echogenicity of the liver parenchyma, an accentuated echogenicity difference between the liver and the renal cortex, blurring of the portal vein and diaphragm images, and attenuation of the ultrasound signal in deep layers. However, the method has limited sensitivity for mild steatosis. Modern quantitative ultrasound technologies allow for a more objective assessment of liver fat content, while elastography enables the detection of fibrosis risk. A 2025 systematic review confirmed the potential of modern ultrasound methods for the non-invasive detection of steatosis and fibrosis.
Conclusion. Ultrasonography remains a primary, safe, widely available, and cost-effective instrumental method for detecting metabolic dysfunction-associated steatotic liver disease. At the same time, the modern clinical approach requires integrating standard B-mode ultrasound with clinical and laboratory data, blood-based indices such as FIB-4, and—when necessary elastography and other quantitative imaging techniques.
References
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031.
European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obesity Facts. 2024;17(4):374–444. doi:10.1159/000539371.
Pozowski P., Bilski M., Bedrylo M., Sitny P., Zaleska-Dorobisz U. Modern ultrasound techniques for diagnosing liver steatosis and fibrosis: A systematic review with a focus on biopsy comparison. World Journal of Hepatology. 2025;17(2):100033.
doi:10.4254/wjh.v17.i2.100033.
Lai J.C.T., et al. The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastogra-phy. Ultrasonography. 2025. doi:10.14366/usg.24219.
Barr R.G. Multiparametric Ultrasound for Chronic Liver Disease Radiologic Clinics of North America. 2025;63(1):13–28. doi:10.1016/j.rcl.2024.07.003.
Biris A.I., Karamatzanis I., Biri D., Biris I.A., Maravegias N. Non-Invasive Ultrasound Diagnostic Techniques for Steatotic Liver Disease and Focal Liver Lesions: 2D, Colour Doppler, 3D, Two-Dimensional Shear Wave Elastography (2D-SWE), and Ultrasound-Guided Attenuation Parameter (UGAP). Cureus. 2024;16(10):e72087. doi:10.7759/cureus.72087.
Santoro S., Khalil M., Abdallah H., et al. Early and accurate diagnosis of steatotic liver by artificial intelligence (AI)-supported ultrasono-graphy. European Journal of Internal Medicine. 2024;125:57–66. doi:10.1016/j.ejim.2024.03.004.
Ma X., Liu Y., Zhou J., et al. Advances in quantitative ultrasound for metabolic dysfunction-associated steatotic liver disease diagnosis. 2026.
09.2026 16:10]
Tacke F., Horn P., Wong V.W.S., et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology. 2024;81(3):492–542.
Hernaez R., Lazo M., Bonekamp S., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090.
Karlas T., Petroff D., Sasso M., et al. Individual patient data meta-analysis of controlled attenuation parameter technology for assessing steatosis. Journal of Hepatology. 2017;66(5):1022–1030.
Castaño C., et al. Imaging evaluation for steatotic liver disease: current approaches and emerging technologies. 2025/2026.